As the cost of Korean medicine treatment for patients with minor injuries under auto insurance has risen rapidly, insurers and regulators have stepped up oversight. In particular, the per-patient cost of treatment at Korean medicine hospitals increased from 856,000 won in 2020 to 1.083 million won last year, while the cumulative auto insurance loss ratio for the first half of this year reached 84.5%, making cost control a broader policy issue rather than a matter of isolated disputes. In response, both institutional reforms requiring additional review for prolonged treatment and legal action by insurers are moving forward. A system is being pushed under which treatment extending beyond eight weeks would require confirmation of medical necessity and an appropriate treatment period, while Samsung Fire & Marine Insurance has filed lawsuits against 52 hospitals, showing how disputes over the appropriateness of Korean medicine treatment are spreading across the field.

Domestic biotech companies are moving into a phase where the value of candidate substances is proven through actual clinical entry and first patient dosing. IKS04, which uses the LigaChemBio platform, received approval for an investigational new drug application in the United States; Cellbion’s pocuvotide entered combination clinical trials with an immuno-oncology drug; and CGBio’s Novosis Putty completed its first procedure in a U.S. confirmatory trial. This trend shows that beyond the achievements of individual companies, the development model itself is being reorganized around late-stage clinical trials and simultaneous global development. In fact, the total number of domestic biopharmaceutical clinical trials rose to 61 in the second quarter, with ADCs accounting for 14 cases, showing that antibody-based therapies are leading development in areas closer to commercialization.

Discussion of automation in logistics did not begin as a simple technology experiment, but from the limits of the labor structure. Truck driver shortages have already emerged in major regions, and in Korea the average general freight driver is 56.4 years old, slowing new entry and making it difficult to maintain transport networks stably through conventional methods alone. As a result, autonomous freight transport is moving from a future concept into actual operations. The case of Liflucks beginning paid freight service between the Southeast Logistics Complex in Songpa, Seoul, and a logistics center in Jincheon, North Chungcheong Province, shows that the goal of technology validation is shifting away from travel convenience toward logistics uptime and supply stability...

The government's primary care innovation pilot program was designed to enable local clinics to continuously manage registered middle-aged and older patients, and it began by limiting eligibility to clinic-level medical institutions and selecting 100 sites in total. More than a simple support program, it is intended to test a family doctor-style care system centered on prevention and counseling, making the question of who should take responsibility for local primary care a core institutional issue. The strong backlash from the Korean medicine community stems less from the compensation amount itself than from concerns over where regional patients and National Health Insurance funds will flow in the future. Citing the fact that Korean medicine clinics had meaningful participation in an earlier primary care home-visit pilot program, they are calling for broader eligibility, and this dispute can be seen as another case in which a long-running inter-professional conflict has resurfaced through fee schedules and program design.

On the 23rd, the Ministry of Food and Drug Safety found 26 cases during an online inspection in which advertisements made ordinary foods or cosmetics appear to be products close to pharmaceuticals. In particular, as interest in health functional foods claiming body fat reduction has grown, consumers have become more likely to expect benefits that go beyond the actual approved scope. The problem is that these advertisements rely more on staging than on the products themselves. Devices such as fictitious doctors or pharmacists created with generative AI manufacture a sense of trust, and with more cases of consumers buying through SNS ads only to struggle to verify sellers or obtain refunds, the limits of existing labeling regulations in adequately protecting consumers have become clear.